Allogene Therapeutics, Inc. (ALLO)
NASDAQ
1.25
0.00 (0.00%)
Closed
Oct 23, 2026
Day's Range
1.161.26
52 wk Range
1.044.46
Financial Statements - ALLO - Allogene Therapeutics, Inc.
Revenue
0▼ 100.0%
Net Income
-190.88M▲ 25.9%
EBITDA
-175.07M▲ 23.1%
Free Cash Flow
-149.63M▲ 25.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 22K | 95K | 156K | 114.08M | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -206.93M | -257.48M | -314.49M | -335.53M | -180.19M | -258.24M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -2.16M | -19.63M | -31.08M | -9.44M | -3.57M | -67.30M |
| Pre Tax Income | -190.88M | -257.14M | -327.26M | -340.41M | -182.05M | -316.38M |
| Income Tax | 0 | 443K | - | - | 0 | 0 |
| Net Income | -190.88M | -257.59M | -327.26M | -340.41M | -182.05M | -316.38M |
| EPS Basic | -0.87 | -1.32 | -2.09 | -2.32 | -1.89 | -2.08 |
| EPS Diluted | -0.87 | -1.32 | -2.09 | -2.32 | -1.89 | -2.08 |
| Basic Shares Outstanding | 220.62M | 194.81M | 156.93M | 143.14M | 135.82M | 120.37M |
| Diluted Shares Outstanding | 220.62M | 194.81M | 156.93M | 143.14M | 135.82M | 120.37M |
| Ebit | -189.81M | -256.96M | -314.49M | -335.53M | -180.19M | -258.24M |
| Ebitda | -175.07M | -227.61M | -287.04M | -321.24M | -169.73M | -250.65M |
| Net Income Continuous Operations | -190.88M | -257.59M | -327.26M | -340.41M | -182.05M | -316.38M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
